Adjunctive empagliflozin therapy in endocrine-driven heart failure with preserved ejection fraction after thyroid cancer surgery
Clinical Endocrinology and Endocrine Surgery · 30.06.2026 · (2) · 26-33
DOI: 10.30978/cees-2026-2-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology and Endocrine Surgery, online erschienen am 30.06.2026. Verfasst von O. M. Didushko und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Survivors of differentiated thyroid cancer after total thyroidectomy form a growing population with increased long-term cardiovascular risk related to chronic thyroid hormone imbalance and lifelong L-thyroxine replacement. In this setting, hypothyroid cardiomyopathy with preserved left ventricular ejection fraction is associated with elevated N-terminal fragment of pro-B-type natriuretic pept ide (NT-proBNP), diastolic dysfunction, atrial remodeling and endothelial impairment. Data on disease-modifying treatment for this endocrine-driven heart failure with preserved ejection fraction (HFpEF)-like phenotype remain limited. Objective — to assess the effect of adding empagliflozin to standard beta-blocker and angiotensin-converting enzyme inhibitor therapy on left ventricular diastolic function, endothelial function and galectin-3 levels in post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction. Materials and methods. This prospective controlled study included 61 adults (57,2±7,3 years, 48 female, 23 male) after total thyroidectomy for thyroid cancer with heart failure symptoms, elevated NT-proBNP and left ventricular ejection fraction ≥50%. Patients received either standard therapy or standard therapy plus empagliflozin 10 mg/day for 6 months.
Results
Baseline clinical characteristics, thyroid status, L-thyroxine dose and NT-proBNP levels were comparable between groups. Standard therapy alone produced only modest improvement in diastolic indices, flow-mediated dilation (FMD), galectin-3 and NT-proBNP. In contrast, empagliflozin was associated with greater reductions in E/e′, larger increases in e′ velocities, a more pronounced decrease in left atrial volume index, stronger improvement in FMD, and greater declines in galectin-3 and NT-proBNP. In multivariable linear mixed-effects models, time × treatment interactions for E/e′ FMD, galectin-3 and NT-proBNP remained significant. Empagliflozin was well tolerated, with no serious drug-related adverse events.
Conclusions
In post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction, empagliflozin added to standard therapy was associated with greater improvement in diastolic and endothelial function and with larger reductions in galectin-3 and NT-proBNP than standard treatment alone. These findings support its potential cardio- and vasculoprotective role in endocrine-driven HFpEF phenotypes and justify larger randomized trials.
Zitieren
APA
Didushko, O. M., Bielinskyi, M. V., Herashchenko, A. S., Nyshchuk-Oliinyk, N. B., Tkachuk-Hryhorchuk, O. O., & Pavliskyi, A. Y. (2026). Adjunctive empagliflozin therapy in endocrine-driven heart failure with preserved ejection fraction after thyroid cancer surgery. Clinical Endocrinology and Endocrine Surgery, 26-33. https://doi.org/10.30978/cees-2026-2-26
Vancouver
Didushko OM, Bielinskyi MV, Herashchenko AS, Nyshchuk-Oliinyk NB, Tkachuk-Hryhorchuk OO, Pavliskyi AY. Adjunctive empagliflozin therapy in endocrine-driven heart failure with preserved ejection fraction after thyroid cancer surgery. Clinical Endocrinology and Endocrine Surgery. 2026:26-33. doi:10.30978/cees-2026-2-26
BibTeX
@article{Didushko2026,
author = {Didushko, O. M. and Bielinskyi, M. V. and Herashchenko, A. S. and Nyshchuk-Oliinyk, N. B. and Tkachuk-Hryhorchuk, O. O. and Pavliskyi, A. Y.},
title = {Adjunctive empagliflozin therapy in endocrine-driven heart failure with preserved ejection fraction after thyroid cancer surgery},
journal = {Clinical Endocrinology and Endocrine Surgery},
year = {2026},
number = {2},
pages = {26--33},
doi = {10.30978/cees-2026-2-26}
}
EUVIMED